Skuldtech Receives $1.3M for Alzheimer's Dx Development | GenomeWeb

NEW YORK (GenomeWeb News) – French biomarker firm Skuldtech today announced it has been awarded €1 million ($1.3 million) in funding to support work on developing diagnostic tests for an Alzheimer's drug in development.

The funding is from Bpifrance, a French public financing structure, and is part of a project on Alzheimer's that has received €8.6 million in total funding. The program, Skuldtech said, is anticipated to last four years with the first results expected in 2018.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.